M. S. Kostapanos, H. J. Milionis, K. G. Lagos, C. B. Rizos, A. D. Tselepis and M. S. Elisaf, “Baseline Triglyceride Levels and Insulin Sensitivity Are Major Determinants of the Increase of LDL Particle Size and Buoyancy Induced by Rosuvastatin Treatment in Patients with Primary Hyper-lipidemia,” European Journal of Pharmacology, Vol. 590, No. 1-3, 2008, pp.327-332. doi:10.1016/j.ejphar.2008.06.007

has been cited by the following article:

• TITLE: Rosuvastatin Reduces Plasma Small Dense Ldl-Cholesterol Predominantly in Non-Diabetic Hypercholesterolemic Patients

  AUTHORS: Gen Yoshino, Saburo Nakano, Tomoko Matsumoto, Eiichi Murakami, Toshisuke Morita, Koji Kuboki

  KEYWORDS: Rosuvastatin; Small Dense LDL-Cholesterol (sdLDL); Large Buoyant LDL-C (lbLDL-C); Apolipoprotein (apo) B; Small Dense LDL-Cholesterol (sdLDL)/Large Buoyant LDL-C (lbLDL-C) Ratio

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.3 No.1, January 12, 2012

  ABSTRACT: Aims: Small dense LDL (sdLDL) cholesterol is considered a cardiovascular risk. Our purpose in this study was to evaluate the efficacy of rosuvastatin in reducing sdLDL and large buoyant LDL (lbLDL-C) in hypercholesterolemia. Methods: Fifty-six patients with a mean baseline LDL-cholesterol (LDL-C) concentration of 173.9 ± 40.5 mg/dL were treated with rosuvastatin 2.5 mg/day for 12 weeks. LDL-C, sdLDL-C, and apolipoprotein (apo) B were assessed and l lbLDL-C was calculated (LDL-C minus sdLDL-C). Results: After 12-week treatment with rosuvastatin 2.5mg, sdLDL-C and lbLDL-C were significantly reduced from 62.1 ± 23.8 mg/dL to 34.0 ± 13.4 mg/dL, p